- Record: found
- Abstract: found
- Article: not found
Quality-of-life effects of prostate-specific antigen screening.
Eveline A M Heijnsdijk
1 ,
Elisabeth M Wever ,
Anssi Auvinen ,
Jonas Hugosson ,
Stefano Ciatto ,
Vera Nelen ,
Maciej Kwiatkowski ,
Arnauld Villers ,
Alvaro Páez ,
Sue M Moss ,
Marco Zappa ,
Teuvo L J Tammela ,
Tuukka Mäkinen ,
Sigrid Carlsson ,
Ida J Korfage ,
Marie-Louise Essink-Bot ,
Suzie J Otto ,
Gerrit Draisma ,
Chris H Bangma ,
Monique J Roobol ,
Fritz H Schröder ,
Harry J de Koning
Aug 16 2012
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
After 11 years of follow-up, the European Randomized Study of Screening for Prostate Cancer (ERSPC) reported a 29% reduction in prostate-cancer mortality among men who underwent screening for prostate-specific antigen (PSA) levels. However, the extent to which harms to quality of life resulting from overdiagnosis and treatment counterbalance this benefit is uncertain.
Related collections
Author and article information
Comments
Comment on this article
scite_
Similar content517
- Geotemporospatial and causal inferential epidemiological overview and survey of USA cannabis, cannabidiol and cannabinoid genotoxicity expressed in cancer incidence 2003–2017: part 3 – spatiotemporal, multivariable and causal inferential pathfinding and exploratory analyses of prostate and ovarian cancersAuthors: Albert Reece, Gary Kenneth Hulse